drugset / Trial / NCT06691685
A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating Relapsed/Refractory Multiple Myeloma.
Phase 0
Recruiting
24 enrolled
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Shenzhen Pregene Biopharma Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability, preliminary efficacy and immunogenicity of ESO-T01 for patients with relapsed/refractory multiple myeloma.
Timeline
- Start
- 2024-11-18
- Primary completion
- 2027-11-01
- Completion
- 2027-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BCMA CAR-T | Cell therapy | — | Intravenous |